William Blair analyst Andrew Brackmann has reiterated their bullish stance on LH stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Brackmann has given his Buy rating due to a combination of factors, despite the mixed nature of Labcorp’s latest quarter. While revenue fell short and diagnostic volumes grew more slowly than expected, he views the main headwinds—such as reduced orders from a consumer genetics client and temporary weather effects—as peripheral to the long‑term story.
He places greater weight on the company’s 2026 outlook, which projects revenue and adjusted earnings ahead of market expectations and suggests ongoing strength in the core diagnostics business alongside improving profitability in biopharma lab services. In his view, Labcorp is positioned to capitalize on steady demand, resilient pricing, and a robust acquisition pipeline, supporting durable earnings growth and a reliable dividend, which underpins his Outperform recommendation and positive stance on the valuation.
According to TipRanks, Brackmann is a 4-star analyst with an average return of 21.2% and a 64.29% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Abbott Laboratories.
In another report released today, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $311.00 price target.